Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Calvin Snipes

Internal Medicine Easley, SC Medical Doctor

NPI 1225023484 CMS profile 327696

1648 Gentry Memorial Hwy, Easley, SC 29640

Open in the dashboard

General payments

$4,463

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Calvin Snipes of Easley, SC is reported in the CMS Open Payments database as having received $4,463 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52 3
2023 General $701 42
2022 General $1,149 76
2021 General $629 47
2020 General $672 42
2019 General $1,261 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Calvin Snipes
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Calvin Snipes were reported at $52. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Calvin Snipes Internal Medicine median Middle half National median
2019 $1,261 $159 $48–$570 $163
2020 $672 $119 $33–$402 $114
2021 $629 $135 $37–$521 $132
2022 $1,149 $141 $42–$496 $149
2023 $701 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $52 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $796 58 payments
  2. Janssen Pharmaceuticals, Inc $475 27 payments
  3. Lilly USA, LLC $394 26 payments
  4. Amgen Inc. $387 27 payments
  5. Novartis Pharmaceuticals Corporation $352 18 payments
  6. AbbVie, Inc. $247 16 payments
  7. GlaxoSmithKline, LLC. $240 18 payments
  8. Pfizer Inc. $188 13 payments
  9. AstraZeneca Pharmaceuticals LP $165 12 payments
  10. Dexcom, Inc. $123 7 payments
  11. Other $1,098 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,463 289 payments
Products named General payments · program years 2019–2025
  1. Ozempic $544 44 payments
  2. RYBELSUS $452 35 payments
  3. Tresiba $339 19 payments
  4. XARELTO $292 21 payments
  5. ENTRESTO $281 13 payments
  6. AIMOVIG $276 19 payments
  7. MOUNJARO $216 15 payments
  8. Repatha $197 16 payments
  9. INVOKANA $196 13 payments
  10. TRELEGY ELLIPTA $176 14 payments
  11. Other $3,164 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 215 drugs

Part D claims

16,630

Median for Internal Medicine: 777

Drug cost

$1,232,802

Median for Internal Medicine: $73,373

Branded share of claims

20.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 121 $163,399
Eliquis Apixaban Brand 132 $105,840
Ozempic Semaglutide Brand 93 $90,315
Jardiance Empagliflozin Brand 71 $75,685
Repatha Sureclick Evolocumab Brand 68 $60,663
Prolia Denosumab Brand 32 $55,905
Januvia Sitagliptin Phosphate Brand 60 $53,816
Xarelto Rivaroxaban Brand 65 $48,753
Tresiba Flextouch U-100 Insulin Degludec Brand 76 $43,566
Tresiba Flextouch U-200 Insulin Degludec Brand 48 $42,363

The 10 drugs with the highest cost, of 215 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$145,017

Of which drugs: $15,927

Medicare patients

488

Average age 77

Services billed

3,718

177 women, 311 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 31%
Ischemic heart disease 30%
Diabetes 25%
Atrial fibrillation 25%
Depression 19%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 118 118 $9,655
Pcv20 vaccine im 90677 Office 18 18 $4,726
Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage 90694 Office 18 18 $1,365
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 54 $30
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 63 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record